Ekso Bionics (EKSO) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

EKSO Stock Forecast

Ekso Bionics stock forecast is as follows: an average price target of $2.00 (represents a 244.77% upside from EKSO’s last price of $0.58) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

EKSO Price Target

The average price target for Ekso Bionics (EKSO) is $2.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $2.00 to $2.00. This represents a potential 244.77% upside from EKSO's last price of $0.58.

EKSO Analyst Ratings

Buy

According to 8 Wall Street analysts, Ekso Bionics's rating consensus is 'Buy'. The analyst rating breakdown for EKSO stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Ekso Bionics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 29, 2024	Ben Haynor	Lake Street	$2.00	$1.13	76.99%	244.77%

The latest Ekso Bionics stock forecast, released on Oct 29, 2024 by Ben Haynor from Lake Street, set a price target of $2.00, which represents a 76.99% increase from the stock price at the time of the forecast ($1.13), and a 244.77% increase from EKSO last price ($0.58).

Ekso Bionics Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	1
Avg Price Target	-	$2.00	$2.00
Last Closing Price	$0.58	$0.58	$0.58
Upside/Downside	-100.00%	244.77%	244.77%

In the current month, the average price target of Ekso Bionics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ekso Bionics's last price of $0.58. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 29, 2024	Lake Street	Buy	Buy	Hold
Oct 29, 2024	Needham	Buy	Buy	Hold
Oct 29, 2024	Morgan Stanley	Overweight	Overweight	Hold
Oct 29, 2024	BTIG	Buy	Buy	Hold
Oct 29, 2024	Barclays		Overweight	Upgrade
Oct 29, 2024	Telsey Advisory	Market Perform	Market Perform	Hold
Oct 29, 2024	JMP Securities	Market Outperform	Market Outperform	Hold
Oct 29, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 24, 2024	Lake Street		Buy	Initialise

Ekso Bionics's last stock rating was published by Lake Street on Oct 29, 2024. The company gave EKSO a "Buy" rating, the same as its previous rate.

Ekso Bionics Financial Forecast

Ekso Bionics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	-	$4.70M	$4.12M	$3.55M	$3.33M	$3.46M	$2.57M	$4.08M	$3.05M	$2.21M	$1.91M	$2.25M	$2.90M	$2.26M	$1.47M	$3.72M	$3.32M	$3.26M	$3.62M	$2.52M	$1.44M
Avg Forecast	$7.75M	$6.15M	$6.20M	$5.05M	$5.30M	$5.55M	$5.15M	$5.00M	$4.80M	$4.50M	$4.40M	$2.80M	$3.94M	$3.58M	$3.49M	$3.20M	$2.76M	$2.58M	$2.14M	$3.00M	$2.58M	$2.45M	$1.62M	$1.41M	$3.65M	$3.15M	$4.24M	$3.90M	$2.02M	$1.52M
High Forecast	$8.03M	$6.37M	$6.43M	$5.23M	$5.49M	$5.75M	$5.34M	$5.18M	$4.97M	$4.66M	$4.56M	$2.90M	$4.08M	$3.58M	$3.49M	$3.20M	$2.76M	$2.58M	$2.14M	$3.00M	$2.58M	$2.45M	$1.62M	$1.41M	$3.65M	$3.15M	$4.24M	$3.90M	$2.42M	$1.82M
Low Forecast	$7.47M	$5.93M	$5.97M	$4.87M	$5.11M	$5.35M	$4.96M	$4.82M	$4.63M	$4.34M	$4.24M	$2.70M	$3.79M	$3.58M	$3.49M	$3.20M	$2.76M	$2.58M	$2.14M	$3.00M	$2.58M	$2.45M	$1.62M	$1.41M	$3.65M	$3.15M	$4.24M	$3.90M	$1.61M	$1.21M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	2	2	3	4	7	9
Surprise %	-	-	-	-	-	-	-	-	-	-	1.07%	1.47%	0.90%	0.93%	0.99%	0.80%	1.48%	1.18%	1.03%	0.64%	0.87%	1.18%	1.40%	1.04%	1.02%	1.05%	0.77%	0.93%	1.25%	0.95%

Ekso Bionics's average Quarter revenue forecast for Sep 23 based on 1 analysts is $4.50M, with a low forecast of $4.34M, and a high forecast of $4.66M. EKSO's average Quarter revenue forecast represents a -4.32% decrease compared to the company's last Quarter revenue of $4.70M (Jun 23).

Ekso Bionics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	2	2	3	4	7	9
EBITDA	-	-	-	-	-	-	-	-	-	-	$-4.28M	$-4.04M	$-4.47M	$-3.48M	$-2.90M	$-4.36M	$-2.70M	$-1.78M	$-1.10M	$-3.52M	$-3.79M	$2.62M	$-11.57M	$-2.32M	$-2.48M	$320.00K	$-2.71M	$-6.18M	$-7.31M	$-7.74M
Avg Forecast	$-6.70M	$-5.32M	$-5.36M	$-4.37M	$-4.58M	$-4.80M	$-4.45M	$-6.06M	$-4.15M	$-3.89M	$-3.81M	$-5.51M	$-3.20M	$-3.39M	$-3.31M	$-5.01M	$-2.61M	$-2.44M	$-2.03M	$-2.26M	$-2.44M	$-2.32M	$-1.53M	$-2.96M	$-3.45M	$-2.99M	$-4.02M	$-4.64M	$-5.48M	$-8.12M
High Forecast	$-6.46M	$-5.13M	$-5.17M	$-4.21M	$-4.42M	$-4.63M	$-4.29M	$-4.85M	$-4.00M	$-3.75M	$-3.67M	$-4.41M	$-2.56M	$-3.39M	$-3.31M	$-4.00M	$-2.61M	$-2.44M	$-2.03M	$-1.81M	$-2.44M	$-2.32M	$-1.53M	$-2.37M	$-3.45M	$-2.99M	$-4.02M	$-3.71M	$-4.39M	$-6.50M
Low Forecast	$-6.95M	$-5.51M	$-5.56M	$-4.53M	$-4.75M	$-4.98M	$-4.62M	$-7.27M	$-4.30M	$-4.03M	$-3.94M	$-6.61M	$-3.84M	$-3.39M	$-3.31M	$-6.01M	$-2.61M	$-2.44M	$-2.03M	$-2.71M	$-2.44M	$-2.32M	$-1.53M	$-3.56M	$-3.45M	$-2.99M	$-4.02M	$-5.56M	$-6.58M	$-9.75M
Surprise %	-	-	-	-	-	-	-	-	-	-	1.13%	0.73%	1.39%	1.03%	0.88%	0.87%	1.03%	0.73%	0.54%	1.56%	1.55%	-1.13%	7.55%	0.78%	0.72%	-0.11%	0.68%	1.33%	1.33%	0.95%

6 analysts predict EKSO's average Quarter EBITDA for Dec 20 to be $-2.44M, with a high of $-2.44M and a low of $-2.44M. This is -193.30% lower than Ekso Bionics's previous annual EBITDA (Sep 20) of $2.62M.

Ekso Bionics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	2	2	3	4	7	9
Net Income	-	-	-	-	-	-	-	-	-	-	$-4.23M	$-4.20M	$-2.05M	$-4.95M	$-2.73M	$-5.00M	$-2.90M	$-1.96M	$-1.27M	$-3.67M	$-3.98M	$2.45M	$-11.77M	$-2.53M	$-2.72M	$206.00K	$-3.07M	$-6.55M	$-7.90M	$-8.30M
Avg Forecast	$-304.65K	$-1.02M	$-913.95K	$-1.52M	$-1.52M	$-2.13M	$-2.64M	$-6.27M	$-2.23M	$-6.30M	$-5.69M	$-5.70M	$-3.40M	$-4.37M	$-4.37M	$-5.18M	$-4.56M	$-4.56M	$-4.56M	$-2.35M	$-5.47M	$-7.11M	$-10.11M	$-3.24M	$-11.85M	$-19.14M	$-21.87M	$-4.91M	$-5.93M	$-8.72M
High Forecast	$-290.24K	$-967.48K	$-870.73K	$-1.45M	$-1.45M	$-2.03M	$-2.52M	$-5.02M	$-2.13M	$-6.00M	$-5.42M	$-4.56M	$-2.72M	$-4.37M	$-4.37M	$-4.15M	$-4.56M	$-4.56M	$-4.56M	$-1.88M	$-5.47M	$-7.11M	$-10.11M	$-2.59M	$-11.85M	$-19.14M	$-21.87M	$-3.93M	$-4.74M	$-6.97M
Low Forecast	$-319.06K	$-1.06M	$-957.16K	$-1.60M	$-1.60M	$-2.23M	$-2.77M	$-7.53M	$-2.34M	$-6.59M	$-5.96M	$-6.84M	$-4.08M	$-4.37M	$-4.37M	$-6.22M	$-4.56M	$-4.56M	$-4.56M	$-2.83M	$-5.47M	$-7.11M	$-10.11M	$-3.89M	$-11.85M	$-19.14M	$-21.87M	$-5.90M	$-7.11M	$-10.46M
Surprise %	-	-	-	-	-	-	-	-	-	-	0.74%	0.74%	0.60%	1.13%	0.62%	0.97%	0.64%	0.43%	0.28%	1.56%	0.73%	-0.34%	1.16%	0.78%	0.23%	-0.01%	0.14%	1.33%	1.33%	0.95%

Ekso Bionics's average Quarter net income forecast for Dec 20 is $-5.47M, with a range of $-5.47M to $-5.47M. EKSO's average Quarter net income forecast represents a -322.97% decrease compared to the company's last Quarter net income of $2.45M (Sep 20).

Ekso Bionics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	2	2	3	4	7	9
SG&A	-	-	-	-	-	-	-	-	-	-	$5.14M	$5.29M	$5.17M	$4.40M	$3.95M	$4.45M	$6.15M	$3.98M	$3.93M	$3.77M	$3.65M	$3.45M	$3.65M	$4.71M	$4.11M	$4.41M	$5.16M	$5.13M	$7.59M	$5.62M
Avg Forecast	$11.05M	$8.77M	$8.84M	$7.20M	$7.56M	$7.91M	$7.34M	$7.13M	$6.85M	$6.42M	$6.27M	$3.99M	$5.61M	$5.11M	$4.98M	$4.56M	$3.94M	$3.67M	$3.05M	$2.42M	$3.68M	$3.49M	$2.31M	$2.01M	$5.20M	$4.50M	$6.05M	$3.84M	$2.87M	$2.16M
High Forecast	$11.45M	$9.09M	$9.16M	$7.46M	$7.83M	$8.20M	$7.61M	$7.39M	$7.09M	$6.65M	$6.50M	$4.14M	$5.82M	$5.11M	$4.98M	$4.56M	$3.94M	$3.67M	$3.05M	$2.90M	$3.68M	$3.49M	$2.31M	$2.01M	$5.20M	$4.50M	$6.05M	$4.61M	$3.45M	$2.59M
Low Forecast	$10.65M	$8.45M	$8.52M	$6.94M	$7.28M	$7.63M	$7.08M	$6.87M	$6.60M	$6.18M	$6.05M	$3.85M	$5.41M	$5.11M	$4.98M	$4.56M	$3.94M	$3.67M	$3.05M	$1.94M	$3.68M	$3.49M	$2.31M	$2.01M	$5.20M	$4.50M	$6.05M	$3.08M	$2.30M	$1.73M
Surprise %	-	-	-	-	-	-	-	-	-	-	0.82%	1.33%	0.92%	0.86%	0.79%	0.97%	1.56%	1.08%	1.29%	1.56%	0.99%	0.99%	1.58%	2.35%	0.79%	0.98%	0.85%	1.33%	2.64%	2.60%

Ekso Bionics's average Quarter SG&A projection for Sep 23 is $6.42M, based on 1 Wall Street analysts, with a range of $6.18M to $6.65M. The forecast indicates a 24.85% rise compared to EKSO last annual SG&A of $5.14M (Jun 23).

Ekso Bionics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	6	3	3	3	2	2	3	4	7	9
EPS	-	-	-	-	-	-	-	-	-	-	$-0.31	$-0.32	$-0.16	$-0.38	$-0.21	$-0.39	$-0.23	$-0.15	$-0.10	$-0.34	$-0.55	$0.30	$-1.88	$-0.44	$-0.53	$0.04	$-0.65	$-1.51	$-1.97	$-5.69
Avg Forecast	$-0.01	$-0.05	$-0.04	$-0.07	$-0.07	$-0.10	$-0.13	$-0.16	$-0.11	$-0.31	$-0.28	$-0.31	$-0.22	$-0.24	$-0.24	$-0.41	$-0.25	$-0.25	$-0.25	$-0.24	$-0.30	$-0.39	$-0.56	$-0.61	$-0.65	$-1.05	$-1.20	$-1.20	$-1.26	$-0.42
High Forecast	$-0.01	$-0.05	$-0.04	$-0.07	$-0.07	$-0.10	$-0.12	$-0.15	$-0.10	$-0.30	$-0.27	$-0.30	$-0.21	$-0.24	$-0.24	$-0.41	$-0.25	$-0.25	$-0.25	$-0.24	$-0.30	$-0.39	$-0.56	$-0.61	$-0.65	$-1.05	$-1.20	$-1.20	$-1.01	$-0.34
Low Forecast	$-0.02	$-0.05	$-0.05	$-0.08	$-0.08	$-0.11	$-0.14	$-0.17	$-0.12	$-0.32	$-0.29	$-0.32	$-0.23	$-0.24	$-0.24	$-0.41	$-0.25	$-0.25	$-0.25	$-0.24	$-0.30	$-0.39	$-0.56	$-0.61	$-0.65	$-1.05	$-1.20	$-1.20	$-1.51	$-0.50
Surprise %	-	-	-	-	-	-	-	-	-	-	1.11%	1.03%	0.73%	1.58%	0.88%	0.95%	0.92%	0.60%	0.40%	1.42%	1.83%	-0.77%	3.39%	0.72%	0.82%	-0.04%	0.54%	1.26%	1.56%	13.55%

According to 6 Wall Street analysts, Ekso Bionics's projected average Quarter EPS for Dec 20 is $-0.30, with a low estimate of $-0.30 and a high estimate of $-0.30. This represents a -200.00% decrease compared to EKSO previous annual EPS of $0.30 (Sep 20).

Ekso Bionics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
EKSO	Ekso Bionics	$0.72	$2.00	177.78%	Buy
AKYA	Akoya Biosciences	$2.54	$4.83	90.16%	Buy
LMAT	LeMaitre Vascular	$90.93	$98.00	7.78%	Buy

EKSO Forecast FAQ

Is Ekso Bionics a good buy?

Yes, according to 8 Wall Street analysts, Ekso Bionics (EKSO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of EKSO's total ratings.

What is EKSO's price target?

Ekso Bionics (EKSO) average price target is $2 with a range of $2 to $2, implying a 244.77% from its last price of $0.58. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Ekso Bionics stock go up soon?

According to Wall Street analysts' prediction for EKSO stock, the company can go up by 244.77% (from the last price of $0.58 to the average price target of $2), up by 244.77% based on the highest stock price target, and up by 244.77% based on the lowest stock price target.

Can Ekso Bionics stock reach $1?

EKSO's average twelve months analyst stock price target of $2 supports the claim that Ekso Bionics can reach $1 in the near future.

What are Ekso Bionics's analysts' financial forecasts?

Ekso Bionics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $21M (high $21.76M, low $20.24M), average EBITDA is $-19.897M (high $-18.182M, low $-21.612M), average net income is $-12.568M (high $-11.016M, low $-14.12M), average SG&A $29.95M (high $31.04M, low $28.86M), and average EPS is $-0.47 (high $-0.448, low $-0.492). EKSO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $25.15M (high $26.06M, low $24.24M), average EBITDA is $-21.754M (high $-20.963M, low $-22.545M), average net income is $-3.757M (high $-3.58M, low $-3.935M), average SG&A $35.87M (high $37.17M, low $34.56M), and average EPS is $-0.185 (high $-0.176, low $-0.194).

Did the EKSO's actual financial results beat the analysts' financial forecasts?

Based on Ekso Bionics's last annual report (Dec 2022), the company's revenue was $12.91M, which missed the average analysts forecast of $14.21M by -9.15%. Apple's EBITDA was $-15.586M, beating the average prediction of $-14.91M by 4.53%. The company's net income was $-14.604M, missing the average estimation of $-17.332M by -15.74%. Apple's SG&A was $18.14M, missing the average forecast of $20.27M by -10.48%. Lastly, the company's EPS was $-1.13, beating the average prediction of $-1.11 by 1.80%. In terms of the last quarterly report (Jun 2023), Ekso Bionics's revenue was $4.7M, beating the average analysts' forecast of $4.4M by 6.89%. The company's EBITDA was $-4.284M, beating the average prediction of $-3.806M by 12.56%. Ekso Bionics's net income was $-4.23M, missing the average estimation of $-5.687M by -25.62%. The company's SG&A was $5.14M, missing the average forecast of $6.27M by -18.08%. Lastly, the company's EPS was $-0.31, beating the average prediction of $-0.28 by 10.71%